Associated Genetic Biomarkers
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) (NFKB2) is a gene that encodes a protein that functions as a subunit of the transcription factor complex nuclear factor-kappa-B. The protein activates genes that participate in inflammation and immunity. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as bone cancer, endometrial cancer, and skin cancer.
NFKB2 is altered in 0.98% of all cancers.
The most common alterations in NFKB2 are NFKB2 Mutation (0.02%), NFKB2 P430S (0.00%), NFKB2 D617Y (0.00%), NFKB2 D94E (0.00%), and NFKB2 G359D (0.00%) .
NFKB2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains NFKB2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with NFKB2 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alteration to serve as an inclusion eligibility criterion is NFKB2 Fusion .
Dexamethasone, ixazomib, and lenalidomide are the most frequent therapies in trials with NFKB2 as an inclusion criteria .
Significance of NFKB2 in Diseases
Multiple Myeloma +
NFKB2 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NFKB2 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.